Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Nancy S. Shulman"'
Autor:
Eric Lawitz, Edward Gane, Eric Cohen, John Vierling, Kosh Agarwal, Tarek Hassanein, Parvez S. Mantry, Paul J. Pockros, Michael Bennett, Nyingi Kemmer, Giuseppe Morelli, Jiuhong Zha, Deli Wang, Nancy S. Shulman, Daniel E. Cohen, K. Rajender Reddy
Publikováno v:
Kidney International Reports, Vol 4, Iss 2, Pp 257-266 (2019)
Introduction: Hepatitis C virus (HCV) infection is common in patients with end-stage renal disease. We investigated the safety and efficacy of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) ± dasabuvir (DSV) ± ribavirin (RBV) in 2 phase 3, open-
Externí odkaz:
https://doaj.org/article/4057d33cf90442e09159e38451382b6a
Autor:
Mario G. Pessoa, José V. Ramalho-Madruga, Katia Alves, Estevão P. Nunes, Hugo Cheinquer, Carlos E. Brandão-Mello, Maria C. Mendes-Correa, Maria L. Ferraz, Paulo R.A. Ferreira, Mário R. Álvares-da-Silva, Henrique S. Coelho, Evaldo S. Affonso-de-Araújo, Juvencio Furtado, Raymundo Parana, Giovanni Silva, Sara A. Lari, Li Liu, Rakesh Tripathi, Tami Pilot-Matias, Daniel E. Cohen, Nancy S. Shulman, Ana Martinelli
Publikováno v:
Annals of Hepatology, Vol 17, Iss 6, Pp 959-968 (2018)
Introduction and aim. Approximately 650,000 people in Brazil have chronic hepatitis C virus (HCV) infection. We evaluated the safety and efficacy of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) plus dasabuvir (DSV) with/without ribavirin (RBV) i
Externí odkaz:
https://doaj.org/article/b9fd528e38274baba3f07c3e21f76fb0
Autor:
Pierre Tonnerre, Maxwell Robidoux, Emily O. Dumas, Nancy S. Shulman, Jenna L. Gustafson, Raymond T. Chung, Daniel E. Cohen, Georg M. Lauer, Arthur Y. Kim, Daniel Kvistad, Sakuni T. Silva, Nadia Alatrakchi, Joelle Brown, Charles Carlton-Smith, Jacinta A. Holmes, Hongtao Zhang
Publikováno v:
Journal of Viral Hepatitis. 26:362-372
The role of the endogenous interferon (IFN) system has been well characterized during IFN-based therapy for chronic hepatitis C virus (HCV) infection; less is known for direct-acting antivirals (DAAs). In this phase 3b open-label study, we assessed c
Autor:
Henrique Sérgio Moraes Coelho, Mário Reis Álvares-da-Silva, Ana de Lourdes Candolo Martinelli, Carlos Eduardo Brandão-Mello, Giovanni Faria Silva, Raymundo Paraná, Sara A. Lari, Hugo Cheinquer, Rakesh Tripathi, Li Liu, Maria Lucia Gomes Ferraz, Jose Valdez Ramalho-Madruga, Estevão P. Nunes, Mario G. Pessoa, Evaldo S. Affonso-de-Araújo, Tami Pilot-Matias, Paulo Roberto Abrão Ferreira, Juvencio Furtado, Katia Alves, Maria Cassia Mendes-Correa, Nancy S. Shulman, Daniel E. Cohen
Publikováno v:
Annals of Hepatology, Vol 17, Iss 6, Pp 959-968 (2018)
Introduction and aim: Approximately 650,000 people in Brazil have chronic hepatitis C virus (HCV) infection. We evaluated the safety and efficacy of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) plus dasabuvir (DSV) with/without ribavirin (RBV) i
Autor:
Vasily Isakov, Jeffrey Enejosa, Pavel O. Bogomolov, Xiaotian Chen, M. V. Maevskaya, Olga Znoyko, Viktor Pasechnikov, Dzmitry Paduta, Pavel Ogurtsov, Rolando M Viani, Nancy S. Shulman
Publikováno v:
European Journal of Gastroenterology & Hepatology. 30:1073-1076
OBJECTIVE An estimated 336 per 100 000 people in Russia are infected with hepatitis C virus, including up to 75% with genotype (GT) 1b. In the TURQUOISE-II/-III trials, a 12-week regimen of the direct-acting antiviral agents ombitasvir (OBV), paritap
Autor:
Andrew H. Talal, Emily O. Dumas, Hongtao Zhang, Jennifer King, Andrew J. Ocque, Christophe Hézode, Richard M Rejman, Jiuhong Zha, Gene D. Morse, Barbara M. Bauer, Daniel E. Cohen, Nancy S. Shulman, Danijela Lucic, Jean-Michel Pawlotsky, Gavin Cloherty
Publikováno v:
The Journal of Infectious Diseases. 217:474-482
Background It is unknown whether ribavirin (RBV) coadministration modifies the early rate of decline of hepatitis C virus (HCV) RNA in the liver versus plasma compartments, specifically. Methods This partially randomized, open-label, phase 2 study en
Autor:
Walid M. Awni, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Nancy S. Shulman, Barbara DaSilva-Tillmann, Thomas Podsadecki, Rajeev M. Menon
Publikováno v:
Clinical Drug Investigation. 37:647-657
All-oral direct-acting antiviral regimens that include combinations of ombitasvir, paritaprevir, ritonavir, and dasabuvir with or without ribavirin were evaluated in hepatitis C virus-infected patients in phase II/III clinical studies. The objective
Autor:
Jacob Lalezari, Amit Khatri, Peter Ruane, Jennifer R. King, Rolando M Viani, Michael S. Saag, Laveeza Bhatti, Roger Trinh, Oluwatoyin Adeyemi, David L. Wyles, Nancy S. Shulman, Yiran B Hu
Publikováno v:
The Journal of Infectious Diseases. 215:599-605
Background Ombitasvir/paritaprevir/ritonavir with dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV) is approved for hepatitis C virus (HCV) genotype 1 (GT1) treatment in HIV-1 coinfected patients. In healthy controls, coadministration of OBV/PTV/r + DSV
Autor:
Gregory T. Everson, Julian Zhou, Peter Ferenci, Ellen S. Yetzer, Eric M. Yoshida, Savino Bruno, Pietro Andreone, Curtis Cooper, Nancy S. Shulman, Sophie Le Pogam, Teresita Beltran-Jaramillo, Mercidita T. Navarro, Mitchell L. Shiffman, Athina Voulgari, Isabel Najera, Christophe Hézode, Michael J. Brunda, Stefan Zeuzem
Publikováno v:
Liver International. 35:108-119
Background & Aims Danoprevir is a hepatitis C virus (HCV) protease inhibitor with activity against genotypes (G)1/G4, which is maintained at lower doses by ritonavir-boosting. We report results of a large, randomized, active-controlled phase IIb stud
Autor:
Rolando M Viani, Roger Trinh, Giuliano Rizzardini, Cristina Tural, Pierre-Marie Girard, Yiran B Hu, N. Mobashery, Hartwig H F Klinker, Linda M Fredrick, Edward Gane, Chloe Orkin, Nancy S. Shulman, David L. Wyles, Tami Pilot-Matias, Adriano Lazzarin, Jürgen K. Rockstroh, Sanjay Bhagani, Mark Nelson, Ruth Soto-Malave, Anne F Luetkemeyer
Publikováno v:
Open Forum Infectious Diseases
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Background Ombitasvir, paritaprevir with ritonavir, and dasabuvir (OBV/PTV/r ± DSV) ±ribavirin (RBV) are approved to treat hepatitis C virus (HCV) genotype 1 and 4 infection. Here, we investigate the safety and efficacy of OBV/PTV/r + DSV ±RBV for